The latest business news around the world. Written by Market Business News's very own editorial team to deliver reliable, up to date, and honest news.

CareFusion – Company Information

0

CareFusion is a multinational medical technology corporation headquartered in San Diego, California, USA.

It is publicly listed on the New York Stock Exchange (NYSE) under the stock ticker symbol ‘CFN’.

The company focuses on the development and marketing of technologies, such as:

ChloraPrep® skin prep products, Alaris® infusion pumps, AVEA® and LTV® series of ventilators and respiratory products, Pyxis® automated dispensing and patient identification systems, V. Mueller® and Snowden-Pencer® surgical instruments, and MedMined™ services for data mining surveillance.

Its products are widely used in hospitals throughout the US and around 130 countries worldwide.

The company is comprised of two reportable business segments: Critical Care Technologies and Medical Technologies and Services.

CareFusion was incorporated in Delaware on January 14, 2009, following the spinoff from Cardinal Health on August 31, 2009.

It has a team of approximately 15,000 employees worldwide.

The company’s vision “to improve the safety and lower the cost of healthcare for generations to come.”

Overview

CareFusion logo

  • Chairman and CEO: Kieran Gallahue
  • CFO: Jim Hinrichs
  • Industry: Medical Technology
  • Type: Public
  • Listed on the New York Stock Exchange (NYSE)
  • NYSE stock symbol: CFN
  • S&P 500 Component
  • Revenue: $3.550 billion USD (2013)
  • Net income: $385 million USD (2013)
  • Diluted earnings per share: $1.72 USD (2013)
  • Employees: 15,000
  • Company head office: 3750 Torrey View Court, San Diego, CA 92130, USA
  • Investor relations contact number: 858-617-4621
  • Investor relations email: [email protected]
  • Website: http://www.carefusion.com/

Income data (in $ millions) 2013 2012
Revenue $3,550 $3,598
Cost of products sold $1,700 $1,794
Gross margin $1,850 $1,804
Selling, General and Administrative Expenses $980 $1,033
Research and Development Expenses $192 $164
Restructuring and Acquisition Integration Charges $18 $33
Operating Income $619 $574
Interest Expense and Other, Net $76 $87
Income Before Income Tax $543 $487
Provision for Income Tax $154 $126
Income from Continuing Operations $389 $361
Loss from Discontinued Operations, Net of Tax $(4) $(68)
Net Income $385 $293
Balance sheet data (in $ millions)
Total assets $8,553 $8,488
Total liabilities $3,167 $3,257
Total stockholders’ equity $5,386 $5,231
Common share data (in $)
Earnings per Common Share – Basic $1.74 $1.60
Earnings per Common Share – Diluted $1.72 $1.30

Source: “2013 Annual Report Form 10-K”